Combined modality treatment for rectal cancer

Seminars in Oncology

Volumn 32, Issue 1 SPEC. ISS., 2005, Pages 103-112

  Zhu, Andrew X ^a   Willett, Christopher G ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; BEVACIZUMAB; CAPECITABINE; CELECOXIB; CETUXIMAB; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; LEVAMISOLE; OXALIPLATIN; PROSTAGLANDIN SYNTHASE INHIBITOR; SEMUSTINE; VASCULOTROPIN ANTIBODY;

ACNE; ANUS SPHINCTER; ASTHENIA; BEAM THERAPY; BLEEDING; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CATHETER INFECTION; CHILL; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DERMATITIS; DIARRHEA; DRUG SAFETY; DRUG TOXICITY; EPISTAXIS; FATIGUE; FEVER; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERTENSION; INFECTION; INTERMETHOD COMPARISON; MORBIDITY; MOUTH ULCER; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NAIL DISEASE; NAUSEA; NEUTROPENIA; NONHUMAN; PEROPERATIVE CARE; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROTEINURIA; RADIATION DOSE FRACTIONATION; RADIATION SICKNESS; RADIOSENSITIZATION; RASH; RECTUM CANCER; RECTUM CARCINOMA; RECTUM SURGERY; REVIEW; RISK REDUCTION; SIDE EFFECT; SURVIVAL RATE; THROMBOSIS; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION;

EID: 13844292690     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.09.032     Document Type: Article

References (83)

1. A. Jemal, R.C. Tiwari, T. Murray Cancer statistics, 2004 CA Cancer J Clin 54 2004 8 29
2. R.P. Billingham Conservative treatment of rectal cancer. Extending the indications Cancer 70 1992 1355 1363
3. C.G. Willett, J.E. Tepper, D.S. Kaufman Adjuvant postoperative radiation therapy for rectal adenocarcinoma Am J Clin Oncol 15 1992 371 375
4. R. Bleday, G. Steele Jr Current protocols and outcomes of local therapy for rectal cancer Surg Oncol Clin North Am 9 2000 751 758
5. J.T. Brodsky, G.K. Richard, A.M. Cohen Variables correlated with the risk of lymph node metastasis in early rectal cancer Cancer 69 1992 322 326
6. C.G. Willett, J.E. Tepper, S. Donnelly Patterns of failure following local excision and local excision and postoperative radiation therapy for invasive rectal adenocarcinoma J Clin Oncol 7 1989 1003 1008
7. A. Chakravarti, C.C. Compton, P.C. Shellito Long-term follow-up of patients with rectal cancer managed by local excision with and without adjuvant irradiation Ann Surg 230 1999 49 54
8. C.S. Wong, H. Stern, B.J. Cummings Local excision and post-operative radiation therapy for rectal carcinoma Int J Radiat Oncol Biol Phys 25 1993 669 675
9. L. Fortunato, N.R. Ahmad, R.S. Yeung Long-term follow-up of local excision and radiation therapy for invasive rectal cancer Dis Colon Rectum 38 1995 1193 1199
10. R. Wagman, B.D. Minsky, A.M. Cohen Conservative management of rectal cancer with local excision and postoperative adjuvant therapy Int J Radiat Oncol Biol Phys 44 1999 841 846
11. G.D. Steele Jr, J.E. Herndon, R. Bleday Sphincter-sparing treatment for distal rectal adenocarcinoma Ann Surg Oncol 6 1999 433 441
12. A.H. Russell, J. Harris, P.J. Rosenberg Anal sphincter conservation for patients with adenocarcinoma of the distal rectum Long-term results of Radiation Therapy Oncology Group protocol 89-02 Int J Radiat Oncol Biol Phys 46 2000 313 322
13. S. Blair, J.D. Ellenhorn Transanal excision for low rectal cancers is curative in early-stage disease with favorable histology Am Surg 66 2000 817 820
14. R.S. Chari, D.S. Tyler, M.S. Anscher Preoperative radiation and chemotherapy in the treatment of adenocarcinoma of the rectum Ann Surg 221 1995 778 786
15. B.D. Minsky, A.M. Cohen, N. Kemeny Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy J Clin Oncol 10 1992 79 84
16. B.D. Minsky, A.M. Cohen, W.E. Enker Sphincter preservation with preoperative radiation therapy and coloanal anastomosis Int J Radiat Oncol Biol Phys 31 1995 553 559
17. W.M. Mendenhall, K.I. Bland, E.M. Copeland 3rd Does preoperative radiation therapy enhance the probability of local control and survival in high-risk distal rectal cancer? Ann Surg 215 1992 696 705
18. R.J. Myerson, J.M. Michalski, M.L. King Adjuvant radiation therapy for rectal carcinoma Predictors of outcome Int J Radiat Oncol Biol Phys 32 1995 41 50
19. T.A. Rich, J.M. Skibber, J.A. Ajani Preoperative infusional chemoradiation therapy for stage T3 rectal cancer Int J Radiat Oncol Biol Phys 32 1995 1025 1029
20. M.S. Roh, N. Petrelli, S. Wieand Phase III randomized trial of preoperative versus postoperative multimodality therapy in patients with carcinoma of the rectum (NSABP R-03) Proc Am Soc Clin Oncol 20 2001 123a (abstr 490)
21. A.S. Allal, S. Bieri, A. Pelloni Sphincter-sparing surgery after preoperative radiotherapy for low rectal cancers Feasibility, oncologic results and quality of life outcomes Br J Cancer 82 2000 1131 1137
22. J.F. Bosset, V. Magnin, P. Maingon Preoperative radiochemotherapy in rectal cancer Long-term results of a phase II trial Int J Radiat Oncol Biol Phys 46 2000 323 327
23. R. Sauer Adjuvant versus neoadjuvant combined modality treatment for locally advanced rectal cancer First results of the German Rectal Cancer Study (CAO/ARO/AIO-94) Int J Radiat Oncol Biol Phys 57 2003 S124 S125
24. Gastrointestinal Tumor Study Group Prolongation of the disease-free interval in surgically treated rectal carcinoma N Engl J Med 312 1985 1465 1472
25. J.E. Krook, C.G. Moertel, L.L. Gunderson Effective surgical adjuvant therapy for high-risk rectal carcinoma N Engl J Med 324 1991 709 715
26. B. Fisher, N. Wolmark, H. Rockette Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer Results from NSABP protocol R-01 J Natl Cancer Inst 80 1988 21 29
27. NIH Consensus Conference Adjuvant therapy for patients with colon and rectal cancer JAMA 264 1990 1444 1450
28. Gastrointestinal Tumor Study Group Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum J Clin Oncol 10 1992 549 557
29. M.J. O'Connell, J.A. Martenson, H.S. Wieand Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery N Engl J Med 331 1994 502 507
30. J.E. Tepper, M.J. O'Connell, G.R. Petroni Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer Initial results of Intergroup 0114 J Clin Oncol 15 1997 2030 2039
31. J.E. Tepper, M. O'Connell, D. Niedzwiecki Adjuvant therapy in rectal cancer Analysis of stage, sex, and local control--Final report of intergroup 0114 J Clin Oncol 20 2002 1744 1750
32. S.R. Smalley, J. Benedetti, S. Williamson Intergroup 0144--Phase III trial of 5-FU based chemotherapy regimens plus radiotherapy (XRT) in postoperative adjuvant rectal cancer. Bolus 5-FU vs prolonged venous infusion (PVI) before and after XRT + PVI vs bolus 5-FU + leucovorin (LV) + levamisole (LEV) before and after XRT + bolus 5-FU + LV Proc Am Soc Clin Oncol 2003 (abstr 1006)
33. M. Miwa, M. Ura, M. Nishida Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue Eur J Cancer 34 1998 1274 1281
34. J. Schuller, J. Cassidy, E. Dumont Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients Cancer Chemother Pharmacol 45 2000 291 297
35. P.M. Hoff, R. Ansari, G. Batist Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer Results of a randomized phase III study J Clin Oncol 19 2001 2282 2292
36. E. Van Cutsem, C. Twelves, J. Cassidy Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer Results of a large phase III study J Clin Oncol 19 2001 4097 4106
37. J. Dunst, T. Reese, T. Sutter Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer J Clin Oncol 20 2002 3983 3991
38. J.S. Kim, M.J. Cho, K.S. Song Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer Int J Radiat Oncol Biol Phys 54 2002 403 408
39. N. Androulakis, C. Kouroussis, S. Kakolyris Phase I study of capecitabine combination with radiotherapy as adjuvant treatment for operable rectal cancer Proc Am Soc Clin Oncol 2002 (abstr 2297)
40. S. Ngan, J. Zalcberg, A. Kell A phase I study of capecitabine combined with radiotherapy for locally advanced potentially operable rectal cancer Proc Am Soc Clin Oncol 2001 (abstr 591)
41. D. Cunningham, S. Pyrhonen, R.D. James Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer Lancet 352 1998 1413 1418
42. P. Rougier, E. Van Cutsem, E. Bajetta Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer Lancet 352 1998 1407 1412
43. L.B. Saltz, J.V. Cox, C. Blanke Irinotecan Study Group Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer N Engl J Med 343 2000 905 914
44. J.Y. Douillard, D. Cunningham, A.D. Roth Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer A multicentre randomised trial Lancet 355 2000 1041 1047
45. B.D. Minsky, E. O'Reilly, D. Wong Daily low-dose irinotecan (CPT-11) plus pelvic irradiation as preoperative treatment of locally advanced rectal cancer Proc Am Soc Clin Oncol 1999 (abstr)
46. E.P. Mitchell, P. Anne, R. Fry Combined mordality therapy of locally advanced or recurrent adenocarcinoma of the rectum Report of a pPhase I trial of chemotherapy (CT) with CPT-11, 5-FU and concomitant irradiation (RT) Proc Am Soc Clin Oncol 2001 (abstr 519)
47. V.K. Mehta, C. Cho, J.M. Ford Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer Int J Radiat Oncol Biol Phys 55 2003 132 137
48. A. de Gramont, A. Figer, M. Seymour Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 2000 2938 2947
49. S. Giacchetti, B. Perpoint, R. Zidani Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer J Clin Oncol 18 2000 136 147
50. T. Andre, C. Louvet, E. Raymond Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen Ann Oncol 9 1998 1251 1253
51. S. Brienza, M.A. Bensmaine, P. Soulie Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC) Results from the European compassionate-use program Ann Oncol 10 1999 1311 1316
52. F. Maindrault-Goebel, A. de Gramont, C. Louvet Oncology Multidisciplinary Research Group (GERCOR) Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer Ann Oncol 11 2000 1477 1483
53. F. Maindrault-Goebel, A. de Gramont, C. Louvet High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7) Eur J Cancer 37 2001 1000 1005
54. A. Martoni, E. Mini, C. Pinto [Oxaliplatin: Combinations with thymidylate synthetase inhibitors: two consecutive phase II studies] Tumori 87 2001 A25 A26
55. I. Chau, A. Webb, D. Cunningham Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer Br J Cancer 85 2001 1258 1264
56. M.L. Rothenberg, A.M. Oza, R.H. Bigelow Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin Interim results of a phase III trial J Clin Oncol 21 2003 2059 2069
57. R.M. Goldberg, D.J. Sargent, R.F. Morton A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer J Clin Oncol 22 2004 23 30
58. G. Freyer, N. Bossard, P. Romestaing Addition of oxaliplatin to continuous fluorouracil, l-folinic acid, and concomitant radiotherapy in rectal cancer The Lyon R 97-03 phase I trial J Clin Oncol 19 2001 2433 2438
59. J.P. Gerard, O. Chapet, C. Nemoz Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen The Lyon R0-04 phase II trial J Clin Oncol 21 2003 1119 1124
60. C. Aschele, M.L. Friso, S. Pucciarelli A phase I-II study of weekly oxaliplatin (OXA), 5-fluorouracil (FU) continuous infusion (CI) and preoperative radiotherapy (RT) in locally advanced rectal cancer (LARC) Proc Am Soc Clin Oncol 2002 (abstr 527)
61. D. Sebag-Montefiore, R. Glynne-Jones, S. Falk Preoperative radiation and oxaliplatin in combination with 5-fluorouracil (5-FU) and low-dose leucovorin (LV) in locally advanced rectal cancer Proc Am Soc Clin Oncol 2002 (abstr 580)
62. E. Roca, S. Carraro, C. Cartelli Radiochemotherapy with short daily infusion of low dose oxaliplatin, leucovorin and 5FU in T3-T4 unresectable rectal cancer. A phase II IATTGI study Proc Am Soc Clin Oncol 2002 (abstr 2204)
63. C.S. Williams, M. Mann, R.N. DuBois The role of cyclooxygenases in inflammation, cancer, and development Oncogene 18 1999 7908 7916
64. L.J. Marnett Aspirin and the potential role of prostaglandins in colon cancer Cancer Res 52 1992 5575 5589
65. M. Oshima, J.E. Dinchuk, S.L. Kargman Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2) Cell 87 1996 803 809
66. L. Milas, K. Kishi, N. Hunter Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme J Natl Cancer Inst 91 1999 1501 1504
67. K. Kishi, S. Petersen, C. Petersen Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor Cancer Res 60 2000 1326 1331
68. M. Tsujii, S. Kawano, R.N. DuBois Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential Proc Natl Acad Sci U S A 94 1997 3336 3340
69. J.L. Masferrer, A. Koki, K. Seibert COX-2 inhibitors. A new class of antiangiogenic agents Ann N Y Acad Sci 889 1999 84 86
70. D.H. Gorski, H.J. Mauceri, R.M. Salloum Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin Cancer Res 58 1998 5686 5689
71. H.J. Mauceri, N.N. Hanna, M.A. Beckett Combined effects of angiostatin and ionizing radiation in antitumour therapy Nature 394 1998 287 291
72. N. Ferrara, T. Davis-Smyth The biology of vascular endothelial growth factor Endocr Rev 18 1997 4 25
73. L.G. Presta, H. Chen, S.J. O'Connor Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders Cancer Res 57 1997 4593 4599
74. M.S. Gordon, K. Margolin, M. Talpaz Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer J Clin Oncol 19 2001 843 850
75. K. Margolin, M.S. Gordon, E. Holmgren Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer Pharmacologic and long-term safety data J Clin Oncol 19 2001 851 856
76. H. Hurwitz, L. Fehrenbacher, T. Cartwright Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC) Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC Proc Am Soc Clin Oncol 2003 (abstr 3646)
77. C.G. Willett, Y. Boucher, E. di Tomaso Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat Med 10 2004 145 147
78. N.S. Goldstein, M. Armin Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma Implications for a standardized scoring system Cancer 92 2001 1331 1346
79. D.S. Salomon, R. Brandt, F. Ciardiello Epidermal growth factor-related peptides and their receptors in human malignancies Crit Rev Oncol Hematol 19 1995 183 232
80. D. Cunningham, S. Humblet, S. Siena Cetuximab (C225) alone or in combination with irinotecan CCPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC) Proc Am Soc Clin Oncol 2003 (abstr 1012)
81. L. Saltz Cetuximab (IMC-C225) plus irinotecan (PT-11) is active in CPT011-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR) Proc Am Soc Clin Oncol 2001 (abstr 7)
82. L. Saltz Single agent IMC-C225 (Eribitux) has activity in CPT-11-refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR) Proc Am Soc Clin Oncol 2002 (abstr 504)
83. V. Volter, R. Stupp, M. Matter Preoperative hyperfractionated accelerated radiotherapy (HAER) and concomitant CPT-11 in rectal carcinoma. A phase I/II study Proc Am Assoc Cancer Res 2001 (abstr 2254)